Industry Led Efforts to Clinically Validate ALS Drug Candidates in Jeopardy?

Neuraltus‘ NP001 and Biogen Idec’s dexpramipexole are two high profile experimental ALS drugs currently being investigated in industry sponsored clinical trials. Meanwhile, some frustrated ALS patients, excluded from these trials, have take matters into their own hands, exposing themselves to the potential benefits as well as potential risks of home brewed versions of Neuraltus‘drug or to a reformulation of Biogen Idec‘s drug. The Wall Street Journal reports that these renegade patients are causing some to worry that if adverse events occur in these patients, outside of the FDA-approved studies, this may impede the drug approval process.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail